Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Septerna, Inc. (NASDAQ:SEPN)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 102,749 shares of the company's stock, valued at approximately $2,353,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.23% of Septerna as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in SEPN. RA Capital Management L.P. purchased a new position in shares of Septerna during the 4th quarter worth approximately $160,205,000. TRV GP V LLC purchased a new position in Septerna in the 4th quarter valued at approximately $142,337,000. TRV GP VI LLC purchased a new position in Septerna in the 4th quarter valued at approximately $72,191,000. Samsara BioCapital LLC purchased a new position in Septerna in the 4th quarter valued at approximately $63,399,000. Finally, Driehaus Capital Management LLC purchased a new position in Septerna in the 4th quarter valued at approximately $59,301,000.

Septerna Price Performance

Shares of SEPN traded down $0.31 during midday trading on Friday, reaching $10.21. The stock had a trading volume of 840,163 shares, compared to its average volume of 709,798. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99. The company's fifty day simple moving average is $7.49 and its two-hundred day simple moving average is $12.83.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The company had revenue of $0.22 million for the quarter. Equities analysts forecast that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company raised their price objective on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th. Cantor Fitzgerald raised their price objective on shares of Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, May 16th.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.